Please login to the form below

Not currently logged in
Email:
Password:

Avanir

This page shows the latest Avanir news and features for those working in and with pharma, biotech and healthcare.

Otsuka presses on with Alzheimer’s agitation drug

Otsuka presses on with Alzheimer’s agitation drug

The investigational therapy is a new formulation of the active ingredients in Otsuka/Avanir's already-marketed Nuedexta (deudextromethorphan hydrobromide/quinidine sulphate) product. ... Otsuka and Avanir are also studying AVP-786 in mid-stage trials as

Latest news

  • Avanir’s week goes from bad to worse with Alzheimer’s stumble Avanir’s week goes from bad to worse with Alzheimer’s stumble

    Otsuka’s Avanir unit has been dealt yet another setback after its second phase 3 trial of its new drug for agitation in Alzheimer’s disease missed the mark. ... Otsuka paid $3.5bn to  acquire Avanir in 2014 as part of a strategy to expand its

  • Otsuka’s Alzheimer’s agitation drug hits the mark Otsuka’s Alzheimer’s agitation drug hits the mark

    All three drug classes have side effect issues, including drowsiness. AVP-786 – developed by Otsuka subsidiary Avanir in collaboration with Concert Pharma – offers the promise of a new medicine that could ... bridge the treatment gap” in agitated

  • Otsuka expands CNS presence with Avanir purchase Otsuka expands CNS presence with Avanir purchase

    Deal for US biotech is valued at $3.5bn. Japan-based Otsuka Pharmaceutical has agreed to buy the California biotech Avanir for $3.5bn, expanding its business in diseases of the ... Avanir also has a promising pipeline, including the compound AVP-786,

  • Avanir to co-promote Merck's diabetes drugs in the US Avanir to co-promote Merck's diabetes drugs in the US

    Under the agreement, Avanir will promote these products to healthcare professionals working in long-term care institutional setting, such as care homes. ... Rohan Palekar, chief commercial officer at Avanir, confirmed Merck's ambitions in the area.

  • Genzyme appoints MS and rare diseases business leaders

    He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics